In June 2017, I joined the groups of Wilbert Zwart and André Bergman at the NKI-AVL as a PhD student. Here, my project focuses on improving our understanding of hormonal signaling and acquired hormone therapy resistance in prostate cancer in order to identify novel therapeutic options and contribute to more personalized treatment approaches.
To achieve this, we are performing integrative multi-omics profiling on matched pre- and post-treatment biopsies as part of a clinical trial, which allows us to study how hormone therapies affect the prostate cancer biology and lead to acquired cellular vulnerabilities that can possibly be therapeutically exploited.
Linder, S., van der Poel, H. G., Bergman, A. M., Zwart, W. & Prekovic, S. Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond. Endocr Relat Cancer 26, R31-R52, doi:10.1530/ERC-18-0289 (2018).
Stelloo, S. & Linder, S. et al. Androgen modulation of XBP1 is functionally driving part of the AR transcriptional program. Endocr Relat Cancer 27, 67-79, doi:10.1530/ERC-19-0181 (2020).